GELS logo
GELS NASDAQ AU

Gelteq Limited - Ordinary Shares

Healthcare · Pharmaceuticals Website · IPO Oct 2024
$0.68
▼ $-0.06 (-7.99%)
Vol 17K
2
Quality Score
fail
Mkt Cap
$8.6M
ROE
-57.5%
D/E
26.68
Beta
3.58
52W
$1–$4

Price Chart

Fundamentals Trend

Metric 2025-06-30 2025-09-02 2025-10-02 2025-11-03 2025-12-03 2026-01-02
ROE (TTM) -57.5% -41.0% -41.0% -41.0% -41.0% -57.5%
P/E (TTM)
Net Margin -4011.7%
Gross Margin 30.3%
D/E Ratio 26.68 20.73 20.73 20.73 20.73 26.68
Current Ratio 0.27 0.79 0.79 0.79 0.79 0.27

Key Ratios

ROA (TTM)
-42.7%
P/B
1.5
EPS (TTM)
$-1.05
Rev Growth 3Y
+3.9%
52W High
$4.11
52W Low
$0.77
$0.77 52-Week Range $4.11

Financial Health

Net Debt
$3.9M
Cash
$345K
Total Debt
$4.2M
As of Jun 30, 2025

How does GELS compare to Pharmaceuticals peers?

Peer group: Micro-cap Pharmaceuticals (All) · 171 companies

GELS AARD ACB ACRS ADIL

GELS valuation vs Pharmaceuticals peers

P/E ratio
0% below peers (22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
0% below peers (5.0)
vs Peers
vs Industry
Overvalued
P/B ratio
1.6
27% below peers (2.1)
vs Peers
vs Industry
Pricier
Div yield
0% below peers (2.0%)
vs Peers
vs Industry
Low yield

GELS profitability vs Pharmaceuticals peers

ROE
-57.5%
6% below peers (-54.3%)
vs Peers
vs Industry
In line
Net margin
0% below peers (-47.4%)
vs Peers
vs Industry
Top tier
Gross margin
0% below peers (68.3%)
vs Peers
vs Industry
In line
ROA
-42.7%
14% below peers (-37.4%)
vs Peers
vs Industry
In line

GELS financial health vs Pharmaceuticals peers

D/E ratio
26.7
1632% above peers (1.5)
vs Peers
vs Industry
High debt
Current ratio
0.3
92% below peers (3.4)
vs Peers
vs Industry
Low liquidity
Beta
3.6
281% above peers (0.9)
vs Peers
vs Industry
More volatile

GELS fundamentals radar

GELS Peer median Industry

GELS profitability vs leverage

Bubble size = market cap · X = net margin · Y = D/E ratio

GELS vs peers: key metrics

Top Holders

Top 5: 0.8%
Two Sigma Investments, LP
0.48%
$37K
Wedbush Securities Inc
0.19%
$15K
Virtu Financial LLC
0.13%
$10K
As of Dec 31, 2025

Latest News

No related news yet